Neurofibromatosis-Noonan syndrome: molecular evidence of the concurrence of both disorders in a patient
- PMID: 15948193
- DOI: 10.1002/ajmg.a.30813
Neurofibromatosis-Noonan syndrome: molecular evidence of the concurrence of both disorders in a patient
Abstract
Noonan syndrome (NS) is an autosomal dominant disorder characterized by short stature, facial anomalies, webbed neck, sternal deformity, heart defects, and, in males, cryptorchidism. PTPN11 encodes SHP2, an important component of several signal transduction pathways that acts as a positive regulator of RAS-mitogen activated protein kinase signaling. Neurofibromatosis type 1 (NF1) is another autosomal dominant disorder characterized by hamartomas in multiple organs. The NF1 gene encodes a GAP-related protein, which acts as a negative regulator of the Ras-mediated signal transduction pathway. Clinical overlap between both syndromes, neurofibromatosis-Noonan syndrome (NFNS) is well known. We studied a female patient with typical findings of NFNS and found two mutations: a novel PTPN11 transversion, 1909A --> G, resulting in Gln510Arg, and an NF1 transversion, 2531A --> G, resulting in Leu844Arg. She inherited the PTPN11 mutation from her father and had a de novo NF1 mutation. This is the first report of molecular concurrence of both disorders in the same patient.
Copyright 2005 Wiley-Liss, Inc.
Similar articles
-
Independent NF1 and PTPN11 mutations in a family with neurofibromatosis-Noonan syndrome.Am J Med Genet A. 2009 Jun;149A(6):1263-7. doi: 10.1002/ajmg.a.32837. Am J Med Genet A. 2009. PMID: 19449407
-
Noonan syndrome and neurofibromatosis type I in a family with a novel mutation in NF1.Clin Genet. 2009 Dec;76(6):524-34. doi: 10.1111/j.1399-0004.2009.01233.x. Epub 2009 Oct 21. Clin Genet. 2009. PMID: 19845691
-
NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome.Am J Hum Genet. 2005 Dec;77(6):1092-101. doi: 10.1086/498454. Epub 2005 Oct 26. Am J Hum Genet. 2005. PMID: 16380919 Free PMC article.
-
[Clinical symptoms and molecular pathogenesis of Noonan syndrome--current concepts].Med Wieku Rozwoj. 2006 Jan-Mar;10(1 Pt 2):289-308. Med Wieku Rozwoj. 2006. PMID: 17028394 Review. Polish.
-
Noonan syndrome, PTPN11 mutations, and brain tumors. A clinical report and review of the literature.Am J Med Genet A. 2017 Apr;173(4):1061-1065. doi: 10.1002/ajmg.a.38108. Am J Med Genet A. 2017. PMID: 28328117 Review.
Cited by
-
SHP2 clinical phenotype, cancer, or RASopathies, can be predicted by mutant conformational propensities.Cell Mol Life Sci. 2023 Dec 12;81(1):5. doi: 10.1007/s00018-023-05052-8. Cell Mol Life Sci. 2023. PMID: 38085330 Free PMC article.
-
RASopathy Cohort of Patients Enrolled in a Brazilian Reference Center for Rare Diseases: A Novel Familial LZTR1 Variant and Recurrent Mutations.Appl Clin Genet. 2022 Oct 21;15:153-170. doi: 10.2147/TACG.S372761. eCollection 2022. Appl Clin Genet. 2022. PMID: 36304179 Free PMC article.
-
LZTR1 molecular genetic overlap with clinical implications for Noonan syndrome and schwannomatosis.BMC Med Genomics. 2022 Jul 15;15(1):160. doi: 10.1186/s12920-022-01304-x. BMC Med Genomics. 2022. PMID: 35840934 Free PMC article. Review.
-
A Novel Heterozygous NF1 Variant in a Neurofibromatosis-Noonan Syndrome Patient with Growth Hormone Deficiency: A Case Report.J Clin Res Pediatr Endocrinol. 2023 Nov 22;15(4):438-443. doi: 10.4274/jcrpe.galenos.2022.2021-12-24. Epub 2022 May 31. J Clin Res Pediatr Endocrinol. 2023. PMID: 35633639 Free PMC article.
-
Whole exome analysis of patients in Japan with hearing loss reveals high heterogeneity among responsible and novel candidate genes.Orphanet J Rare Dis. 2022 Mar 5;17(1):114. doi: 10.1186/s13023-022-02262-4. Orphanet J Rare Dis. 2022. PMID: 35248088 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous
